Effect of Deferasirox on Shunt Fraction During Thoracic Surgery With One-Lung Ventilation: A Randomized Controlled Study.
Autor: | Raman R; Department of Anaesthesiology, King George's Medical University, Lucknow, IND., Nair PS; Department of Anaesthesiology, King George's Medical University, Lucknow, IND., Siddiqui AK; Department of Anaesthesiology, King George's Medical University, Lucknow, IND., Prabha R; Department of Anaesthesiology, King George's Medical University, Lucknow, IND., Kohli M; Department of Anaesthesiology, King George's Medical University, Lucknow, IND., Srivastava VK; Department of Anaesthesiology, King George's Medical University, Lucknow, IND. |
---|---|
Jazyk: | angličtina |
Zdroj: | Cureus [Cureus] 2023 May 16; Vol. 15 (5), pp. e39071. Date of Electronic Publication: 2023 May 16 (Print Publication: 2023). |
DOI: | 10.7759/cureus.39071 |
Abstrakt: | Context Deferasirox, an iron chelator, can potentially reduce intraoperative right-to-left shunt and improve oxygenation in patients undergoing thoracic surgery requiring one-lung ventilation (OLV) by potentiating hypoxic pulmonary vasoconstriction (HPV). Aim The aim was to determine the effect of deferasirox on the intraoperative shunt fraction (SF) of patients undergoing thoracic surgery using OLV. Study design and settings This was a prospective, single-blind, randomized, controlled study. The study was conducted at a tertiary-care hospital. Methods Before surgery, 64 patients were allocated to two groups comprising 32 patients each. Group D patients were administered deferasirox, while those in group C were given a placebo. We included patients with the American Society of Anesthesiologists physical status III or IV, aged 18-60 years, undergoing elective thoracic surgery needing OLV. SF was the primary outcome variable. Secondary outcome variables were arterial oxygen tension (PaO Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2023, Raman et al.) |
Databáze: | MEDLINE |
Externí odkaz: |